Those in the HIV vaccine field should read the article by Fouda et al carefully and initiate a more robust discussion of how well-conceived studies in infants can provide new insights on HIV prevention. The log jam in HIV prevention research for HIV vaccines in infants should, with appropriate regulation and safeguards, be lifted and well-thought-out studies of candidate HIV vaccines should be initiated in infants as a priority.